Monday, March 21, 2022
PsyBio Therapeutics (PSYBF)(PSYB:CA)
Acquisition of Everest Pharma Adds Broad Ex-US License
PsyBio Therapeutics is developing biosynthetic psychoactive compounds which offer a new paradigm of treatment to reverse the course of mental health issues. Psychoactive medications treat the illness by rewiring the brain through contemplation and a change of perception in combination with psychotherapy vs. Standard of care (SSRI’s, SNRI’s, MAOI’s, NDRI’s, etc…) which just chemically treat symptoms. Working in partnership with Miami University utilizing a proprietary platform technology to biologically synthesize psilocybin and other targeted next generation active compounds in Psilocybe Cubensis and other fungi and plants.
Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
PsyBio Announced The Acquisition of Everest Pharma Ltd. PsyBio has announced that it will acquire Everest Pharm Ltd, a company based in Lesotho, Africa. The acquisition gives PsyBio an operating license for psychedelic compounds outside North America for activities ranging from cultivation through export of psychedelic compounds.
Increases Research Capabilities The acquisition adds geographic diversification that insulates the company from regulatory or politically-motivated changes that may affect US or Canadian clinical trials or the research environment. This furthers the company’s strategy to actively develop and market products worldwide …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
